"Strategic emerging industries and future industries are the main battlegrounds for developing new quality productivity. The biopharmaceutical industry is not only an important component of the national strategic emerging industries but also a key area for future industry layout." Recently, Ke Xiao, Vice President of the China Association of Traditional Chinese Medicine, stated in a media interview that the Chinese biopharmaceutical industry is undergoing a process from "having" to "excelling". With the assistance of a series of policies and the guidance and implementation of new technologies, China has now established a complete system of the biopharmaceutical industry chain. Its scale of production capacity ranks among the top globally, and the number of research and development of innovative drugs has also entered the second echelon globally. All of these highlight China's transformation from a major pharmaceutical producer to a pharmaceutical powerhouse.
"Biomedical Production Line" (Image provided by interviewee)
"New quality productivity" is a buzzword this year. This year's government work report proposes to "actively foster emerging industries and future industries," including "accelerating the development of frontier emerging industries such as hydrogen energy, new materials, and innovative drugs" and "actively building new growth engines such as biomanufacturing, commercial aerospace, and low-altitude economy."
Currently, although China's biomedical industry has achieved phased results, there are still many aspects that urgently need improvement, such as the original innovation of new drug research and development, high degree of homogenization in pharmaceutical innovation, and low conversion rate of pharmaceutical technology achievements.
Ke Xiao believes that to promote the high-quality development of China's biomedical industry, it is necessary to establish an innovative ecosystem involving the government, universities, research institutions, and pharmaceutical enterprises. This includes further strengthening basic research, protecting intellectual property rights, reducing homogenized competition among enterprises, and enhancing the enthusiasm for industry innovation and R&D investment.
As the President of Kanghong Pharmaceutical, Ke Xiao points out from the perspective of the enterprise that there still exists significant unmet clinical demand in China. With the trend of population aging, the treatment of chronic diseases will constitute a vast application space for the development of new quality productivity for enterprises. Companies should continuously cultivate their own innovative R&D capabilities, seize innovation as the leverage point in the new wave of technological change, and continuously break through development bottlenecks.
At the same time, from the perspective of green industry development, on the basis of the application of new quality productivity in innovative drugs, how to improve production efficiency, reduce energy consumption, and enhance product quality is also the direction for the development and improvement of China's biomedical industry.
Ke Xiao believes that new quality productivity is spawned by revolutionary technological breakthroughs, innovative allocation of production factors, and deep transformation and upgrading of industries. Its essence lies in cultivating contemporary advanced productivity. "China's insistence on fostering original and disruptive technological innovation gives it the opportunity to take a leading position in the global biomedical field, thereby enhancing the country's scientific and technological strength and international competitiveness."
